{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T20:04:48Z","timestamp":1766088288989,"version":"3.40.5"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.critrevonc.2024.104429","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T23:56:02Z","timestamp":1719446162000},"page":"104429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Management of bone disease with concurrent chimeric antigen receptor T-cell therapy for multiple myeloma"],"prefix":"10.1016","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8956-4894","authenticated-orcid":false,"given":"Davis","family":"Kuruvilla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thien","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Nester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chloe","family":"Chose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guston","family":"Zervoudakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.Douglas","family":"Letson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Odion T.","family":"Binitie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas B.","family":"Figura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Costello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciara L.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander L.","family":"Lazarides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.critrevonc.2024.104429_bib1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"18","key":"10.1016\/j.critrevonc.2024.104429_bib2","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104429_bib3","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma","volume":"43","author":"Cocks","year":"2007","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104429_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of bone disease in multiple myeloma: from bench to bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Cancer J."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104429_bib5","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1002\/cncr.20652","article-title":"Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades","volume":"101","author":"Kyle","year":"2004","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104429_bib6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-021-00507-2","article-title":"KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma","volume":"11","author":"Jagannath","year":"2021","journal-title":"Blood Cancer J."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104429_bib7","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104429_bib8","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104429_bib9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"10297","key":"10.1016\/j.critrevonc.2024.104429_bib10","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"16_suppl","key":"10.1016\/j.critrevonc.2024.104429_bib11","doi-asserted-by":"crossref","first-page":"8042","DOI":"10.1200\/JCO.2022.40.16_suppl.8042","article-title":"Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): real-world experience","volume":"40","author":"Hansen","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.critrevonc.2024.104429_bib12","doi-asserted-by":"crossref","first-page":"12052","DOI":"10.1200\/JCO.2023.41.16_suppl.12052","article-title":"Association of frailty and high-risk immuno-nutritional score with outcomes in patients with relapsed and refractory multiple myeloma treated with chimeric antigen receptor T-cells","volume":"41","author":"Modi","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.critrevonc.2024.104429_bib13","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1182\/bloodadvances.2022008320","article-title":"Early cytopenias and infections after standard of care idecabtagene vicleucel\u00a0in relapsed or refractory multiple myeloma","volume":"6","author":"Logue","year":"2022","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104429_bib14","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ijrobp.2018.05.009","article-title":"Radiation therapy for solitary plasmacytoma and multiple myeloma: guidelines from the international lymphoma radiation oncology group","volume":"101","author":"Tsang","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"23","key":"10.1016\/j.critrevonc.2024.104429_bib15","doi-asserted-by":"crossref","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-21-0308","article-title":"The safety of bridging radiation with Anti-BCMA CAR T-cell therapy for multiple myeloma","volume":"27","author":"Manjunath","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2024.104429_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109933","article-title":"Radiation therapy as a bridging and salvage strategy in patients with relapsed or refractory multiple myeloma undergoing BCMA-targeted CAR T-cell therapy","volume":"189","author":"Ababneh","year":"2023","journal-title":"Radio. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104429_bib17","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.ijrobp.2019.05.065","article-title":"Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma","volume":"105","author":"Sim","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104429_bib18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjh.16541","article-title":"Early experience using salvage radiotherapy for relapsed\/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy","volume":"190","author":"Imber","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104429_bib19","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ijrobp.2022.12.017","article-title":"Don't Put the CART before the horse: the role of radiation therapy in Peri-CAR T-cell therapy for aggressive B-cell non-hodgkin lymphoma","volume":"116","author":"Saifi","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"13","key":"10.1016\/j.critrevonc.2024.104429_bib20","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","article-title":"Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma","volume":"4","author":"Pinnix","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2024.104429_bib21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.radonc.2021.11.031","article-title":"Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?","volume":"166","author":"Saifi","year":"2022","journal-title":"Radio. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104429_bib22","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijrobp.2020.05.014","article-title":"Bridging radiation therapy before commercial chimeric antigen receptor T-cell therapy for relapsed or refractory aggressive B-cell lymphoma","volume":"108","author":"Wright","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104429_bib23","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/ajh.27155","article-title":"Incorporating radiation with anti-CD19 chimeric antigen receptor T-cell therapy for relapsed\/refractory non-Hodgkin lymphoma: a multicenter consensus approach","volume":"99","author":"Saifi","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104429_bib24","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.ijrobp.2021.06.038","article-title":"Patterns and predictors of failure in recurrent or refractory large B-cell lymphomas after chimeric antigen receptor T-cell therapy","volume":"111","author":"Figura","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104429_bib25","doi-asserted-by":"crossref","first-page":"259 e1","DOI":"10.1016\/j.jtct.2022.12.021","article-title":"Bridging radiation rapidly and effectively cytoreduces high-risk relapsed\/refractory aggressive B cell lymphomas prior to chimeric antigen receptor T cell therapy","volume":"29","author":"Hubbeling","year":"2023","journal-title":"Transpl. Cell Ther."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104429_bib26","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.ijrobp.2023.06.336","article-title":"Prognostic significance of positron emission tomography delta radiomics following bridging therapy in patients with large B-cell lymphoma undergoing CAR T-cell therapy","volume":"117","author":"Ladbury","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2024.104429_bib27","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1182\/blood-2023-181331","article-title":"Outcomes of BCMA-directed chimeric antigen receptor T-Cell (CART) therapy in patients with relapse-refractory multiple myeloma with extramedullary disease","volume":"142","author":"Dima","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104429_bib28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-020-0280-y","article-title":"Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia","volume":"10","author":"Liu","year":"2020","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2024.104429_bib29","article-title":"The association between glucocorticoid administration and the risk of impaired efficacy of axicabtagene ciloleucel treatment: a systematic review","volume":"12","author":"Sun","year":"2021","journal-title":"Front Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104429_bib30","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11596-021-2373-7","article-title":"Anti-BCMA CAR-T cell therapy in relapsed or refractory multiple myeloma patients with impaired renal function","volume":"41","author":"He","year":"2021","journal-title":"Curr. Med. Sci."},{"key":"10.1016\/j.critrevonc.2024.104429_bib31","article-title":"Dual effects of cyclooxygenase inhibitors in combination with CD19.CAR-T cell immunotherapy","volume":"12","author":"Yang","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2024.104429_bib32","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2147\/TCRM.S79409","article-title":"The unsolved case of \"bone-impairing analgesics\": the endocrine effects of opioids on bone metabolism","volume":"11","author":"Coluzzi","year":"2015","journal-title":"Ther. Clin. Risk Manag"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104429_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11122037","article-title":"Pain management in patients with multiple myeloma: an update","volume":"11","author":"Coluzzi","year":"2019","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104429_bib34","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/leu.2010.62","article-title":"Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease","volume":"24","author":"Terpos","year":"2010","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104429_bib35","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104429_bib36","first-page":"CD003188","article-title":"Bisphosphonates in multiple myeloma: an updated network meta-analysis","volume":"12","author":"Mhaskar","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104429_bib37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1200\/JOP.2011.000486","article-title":"Acute kidney injury and bisphosphonate use in cancer: a report from the research on adverse drug events and reports (RADAR) project","volume":"9","author":"Edwards","year":"2013","journal-title":"J. Oncol. Pr."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104429_bib38","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s12663-019-01211-2","article-title":"Bisphosphonate-induced osteonecrosis of the jaws (BIONJ)","volume":"19","author":"Singh","year":"2020","journal-title":"J. Maxillofac. Oral. Surg."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104429_bib39","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1182\/bloodadvances.2020002378","article-title":"Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study","volume":"5","author":"Terpos","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2024.104429_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.620312","article-title":"Toxicities of chimeric antigen receptor T cell therapy in multiple myeloma: an overview of experience from clinical trials, pathophysiology, and management strategies","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Immunol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104429_bib41","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s11912-022-01240-0","article-title":"Rehabilitation needs for patients undergoing CAR T-cell therapy","volume":"24","author":"Obaisi","year":"2022","journal-title":"Curr. Oncol. Rep."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104429_bib42","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jtct.2022.04.008","article-title":"Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access","volume":"28","author":"Ahmed","year":"2022","journal-title":"Transpl. Cell Ther."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104429_bib43","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.critrevonc.2024.104429_bib44","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1182\/bloodadvances.2022008320","article-title":"Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma","volume":"6","author":"Logue","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2024.104429_bib45","article-title":"Infectious complications of CAR T-cell therapy: a clinical update","volume":"8","author":"Stewart","year":"2021","journal-title":"Ther. Adv. Infect. Dis."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104429_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14061501","article-title":"Cytopenia after CAR-T cell therapy-a brief review of a complex problem","volume":"14","author":"Sharma","year":"2022","journal-title":"Cancers"},{"issue":"15","key":"10.1016\/j.critrevonc.2024.104429_bib47","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104429_bib48","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1007\/s11999-010-1326-4","article-title":"In brief: classifications in brief: Mirels' classification: metastatic disease in long bones and impending pathologic fracture","volume":"468","author":"Jawad","year":"2010","journal-title":"Clin. Orthop. Relat. Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104429_bib49","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/00005131-200408000-00013","article-title":"Management of pathologic fractures of the proximal femur: state of the art","volume":"18","author":"Jacofsky","year":"2004","journal-title":"J. Orthop. Trauma"},{"issue":"17","key":"10.1016\/j.critrevonc.2024.104429_bib50","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/bloodadvances.2020002060","article-title":"Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma","volume":"4","author":"Hashmi","year":"2020","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104429_bib51","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1055\/s-0039-1693120","article-title":"Update on preoperative embolization of bone metastases","volume":"36","author":"Ma","year":"2019","journal-title":"Semin Interv. Radio."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104429_bib52","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104429_bib53","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"oncologist"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104429_bib54","doi-asserted-by":"crossref","first-page":"324","DOI":"10.7861\/clinmedicine.18-4-324","article-title":"Cancer immunotherapy with CAR-T cells - behold the future","volume":"18","author":"Graham","year":"2018","journal-title":"Clin. Med"},{"key":"10.1016\/j.critrevonc.2024.104429_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.879608","article-title":"Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy","volume":"13","author":"Sterner","year":"2022","journal-title":"Front Immunol."},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2024.104429_bib56","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T-cell therapy","volume":"37","author":"Neelapu","year":"2019","journal-title":"Hematol. Oncol."},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2024.104429_bib57","doi-asserted-by":"crossref","first-page":"12770","DOI":"10.1182\/blood-2022-163457","article-title":"Severe persistent cytopenias following CAR T-cell therapy are associated with a decrease in functional hematopoietic stem and progenitor cells","volume":"140","author":"L\u00f3pez","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104429_bib58","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/pmr.2021.0064","article-title":"Early, patient-centered, and multidisciplinary approach in newly diagnosed multiple myeloma: what are we talking about? A case description and discussion","volume":"3","author":"Sorensen","year":"2022","journal-title":"Palliat. Med. Rep."},{"issue":"142","key":"10.1016\/j.critrevonc.2024.104429_bib59","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1182\/blood-2023-181853","article-title":"The BCMA-targeted fourth-generation CAR-T cells secreting CST6 against multiple myeloma and suppresses osteolytic lesions","volume":"1","author":"Sun","year":"2023","journal-title":"Blood. Nov."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824001720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824001720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T11:23:43Z","timestamp":1723634623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824001720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":59,"alternative-id":["S1040842824001720"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104429","relation":{},"ISSN":["1040-8428"],"issn-type":[{"type":"print","value":"1040-8428"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of bone disease with concurrent chimeric antigen receptor T-cell therapy for multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104429","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104429"}}